Stock Selection: Claude Opus 5.5's picks for 2026-10-30
Claude Opus 5.5 picked REGN, XLV, MDLZ, XOM, CL for a 1-day horizon. Portfolio return vs SPY: +1.04%. Picks that beat SPY: 60%.
| Experiment | Stock Selection |
|---|---|
| Model | Claude Opus 5.5 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-30 |
| Measured to | 2026-11-02 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | +1.04% |
| Picks that beat SPY | 60% |
| Benchmark return | +0.31% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | REGN | +5.68% | 58% | +5.37% | Yes |
| 2 | XLV | -0.96% | 56% | -1.27% | No |
| 3 | MDLZ | +2.32% | 54% | +2.01% | Yes |
| 4 | XOM | -1.35% | 52% | -1.66% | No |
| 5 | CL | +1.05% | 51% | +0.74% | Yes |
The model's market view
Risk-off session led by technology: Intel (about -25 to -29%) and Amazon results have revived worries about the payoff from AI capital spending. QQQ was about -2.4% and SPY about -1.1% near 10:00 ET, and S&P 500 was about -1.2% to -1.5% by mid-morning. Money is rotating into defensives. Health care (XLV at an all-time high) and staples are leading, and energy is bid on earnings beats from Exxon and Chevron and WTI near $104 after tanker attacks in the Strait of Hormuz. The picks lean on post-earnings drift in large-cap beat-and-raise names plus the defensive-sector rotation. The main risks are a sharp tech rebound on Monday morning (ISM Manufacturing at 10:00 ET; Apple and Palantir report after Monday's close), weekend Iran ceasefire headlines (Trump said the war is 'going to end soon') that could hit oil, and profit-taking in names that have already gapped up.
Why each pick
REGN
Thesis: Regeneron reported a large Q3 2026 beat. Adjusted EPS was $20.07 against about $16.06-16.25 expected, and revenue was $5.12B (+36% y/y) against about $4.54B. Dupixent, EYLEA HD and Libtayo each hit record sales. The Sanofi development balance is now fully repaid, which structurally lifts collaboration revenue, and the company raised its gross-margin guidance and cut its SG&A guidance. The stock broke well above its prior 52-week high of $859.34 on heavy volume and was among the strongest S&P 500 names on a down day. A fundamental re-rating like this in a low-beta (about 0.15) defensive name tends to keep drifting while tech is under pressure. Risks: after a gain of about 12% intraday, profit-taking or mean reversion into Monday is a real possibility. The analyst average target (about $869-874) is now below the price. Eylea's US franchise is still shrinking, and an FDA decision on cemdisiran is pending. Price: intraday quote of $915.76 (+11.85%) at 10:50 AM ET from Finviz.
XLV
Thesis: Health care is the clearest beneficiary of today's rotation out of AI-exposed tech. XLV rose 2.4% on Thursday while the S&P 500 fell, and it set another all-time high this morning (day high $187.99), helped by strong pharma and biotech prints (Regeneron, Gilead, AbbVie, AstraZeneca, Sanofi, Eli Lilly). Its low beta (about 0.5) helps relative performance if the tech selloff continues into Monday. Risks: XLV has given back part of its opening gain (open $186.75, now about $185.8). If Monday brings a tech or semiconductor relief rally, low-beta defensives would lag SPY. Drug-pricing policy headlines are another risk. Price: intraday quote of $185.82 (+0.97%) at 10:50 AM ET from StockAnalysis.
MDLZ
Thesis: Mondelez's Q3 2026 adjusted EPS of $0.78 beat the roughly $0.71-0.72 consensus. Volume/mix turned positive (+1.8% after -4.6% a year ago), and adjusted gross margin rose 380 bp to 34.2% as cocoa costs ease. The company reaffirmed its 2026 guidance. Several brokers raised targets or reiterated Buy today, including Goldman Sachs (to $75), TD Cowen ($75) and Stifel ($74). Low-beta staples with improving fundamentals benefit from today's defensive rotation, and post-earnings drift supports a further move. Risks: the stock has faded from about +7% premarket to about +4.7%, which signals some supply. Revenue was only in line, and North American consumer softness persists. Price: intraday quote of $65.45 (+4.67% versus the $62.53 close on Oct 29) from The Motley Fool's quote page. That page gave no exact clock time, so it is an intraday, possibly delayed, reading.
XOM
Thesis: ExxonMobil beat Q3 2026 estimates with adjusted EPS of $4.23 against about $4.04-4.13. Refining earned more than upstream for the first time in at least six years, because the disrupted Strait of Hormuz and attacks on Saudi and Russian refineries have widened margins. Exxon raised its dividend to $1.07, cut debt by $8B and committed to $20B of buybacks in 2027. WTI is up about 2% to about $104, and the stock hit an all-time high this morning ($188.50). Energy also has a low correlation to the AI-capex selloff now hitting the index. Risks: the window spans a weekend with live Iran ceasefire talk (Qatari mediators are back in Tehran), so a peace headline could knock oil and refining margins down sharply. The stock already trades above its average analyst target (about $179) and has eased off its opening high. Price: intraday quote of $185.77 (+1.35%) at 10:45 AM ET from Yahoo Finance (Singapore).
CL
Thesis: Colgate-Palmolive's Q3 2026 results beat estimates. Base-business EPS of $0.97 (+7%) topped about $0.93, net sales rose 4.6% and organic sales rose 3.6% with balanced volume (+1.7%) and price (+2%). Gross margin expanded 90 bp, and management raised its full-year gross-margin and EPS guidance while saying input costs are largely locked in for the rest of the year. It is a low-beta (about 0.3) defensive name that benefits from the rotation out of tech and is approaching its 52-week high of $99.33. Risks: the stock has faded from about +5% premarket to about +2.5%. North American sales fell 1.7% on weak volumes, and management flagged soft US consumer sentiment and rising oil-linked packaging and logistics costs. A risk-on tech rebound on Monday would hurt relative performance. Price: intraday quote of $95.50 (+2.47%) at the time of a Benzinga article published during Friday's session. No exact clock time was given, so it is an intraday reading from shortly after the open.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Perplexity | XOM, CVX, LLY, MRK, XLE | -1.43% | 0% |
| Grok 4.7 | REGN, CDNA, LLY, XOM, MDLZ | -0.38% | 40% |
| Muse Spark 1.1 | REGN, XOM, CVX, MDLZ, CDNA | -0.36% | 40% |
| DeepSeek | XOM, XLE, LLY, XLP, XLV | -1.20% | 20% |
| Gemini 3 Pro | LLY, XLV, WMT, XLE, MRK | -0.66% | 20% |
| GPT-6 | XLP, SNY, XOM, RSP, BTSG | -0.30% | 60% |
Written up on ForecastNest Insights: Stock Selection: Claude Opus 5.5's picks for 2026-10-30.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.